Articles for the ‘’ Category

The Clinical Trials Regulation (CTR), effective from January 31, 2022, introduced a pivotal change in the EU’s clinical trial landscape. Transitioning from the previous Clinical Trial Directive (CTD) to the CTR involves submitting a streamlined “transitioning application” before January 30, 2025. This regulatory evolution underscores efficiency and transparency in clinical trials, urging sponsors to initiate the transition process promptly for uninterrupted trial continuity under the CTR.

Both the Belgian legislator and government have played an active role in 2023 when it comes to pharma legislation, which has led to a number of changes in the legal framework. In this article, we look back and discuss five noteworthy developments in Belgian pharma law.